Oncology From preclinical toxicology to clinical safety: The path for... Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.